Related Experiment Video
Updated: Jul 31, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management
Randol Kennedy1, Hussein Awada2, Naga Vura2
1Department of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, OH kennedr@ccf.org.
Abstract:
Immune checkpoint inhibitors are used more and more to treat several types of cancer, significantly extending cancer-free survival. However, concerns are growing about their toxic effects, which are many and varied. Endocrinopathies are some of the most frequently reported adverse effects, and thyroid dysfunction is the most common of these. Here, we review the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, possible factors related to toxicity risk, and principles of management.
Related Concept Videos
Tumor Immunotherapy
Acute Pancreatitis II: Clinical Manifestations and Management
Kidney Transplant III: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Nephrotic Syndrome III : Nursing Management

